Author

Evan Lang

Observed names: E. Lang, Evan Z. Lang, Lang, Evan

Institution: Oncology Hematology Care

Observed institutions: German Cancer Research Center, Sarah Cannon, Knappschaftskrankenhaus Recklinghausen, Essen University Hospital, Oncology Hematology Care, University of Regensburg

ORCID: 0000-0003-3926-0013

Observed ORCID: 0000-0003-3926-0013

OpenAlex ID: A5023890821

Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances

2023 · Evan Lang, Frits van Rhee · Blood Reviews · 30

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

2016 · Johanna C. Bendell, Ahmed Zakari, et al. · Cancer Investigation · 17

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report

2022 · Evan Lang, Brenda Sande, et al. · Therapeutic Advances in Hematology · 13

Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).

2012 · Irfan Firdaus, Kent C. Shih, et al. · Journal of Clinical Oncology · 12

Fokale epitheliale Hyperplasie (Morbus Heck): Beitrag zur viralen Genese

2008 · E. Lang, M. Zabel, et al. · DMW - Deutsche Medizinische Wochenschrift · 9

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

2010 · Ian W. Flinn, Evan Lang, et al. · Blood · 7

Fluorescence diagnosis of skin tumors following topical application of 5-aminolevulinic acid

1998 · G. Ackermann, C. Abels, et al. · Journal of Dermatological Science · 1

Works count: 10

Citation count: 89

H-index: 6

I10-index: 4